Replimune Group
D

REPL

11.445
USD
-0.57
(-4.70%)
Market Closed
Last updated: · Delayed 15 min
Volume
85,276
EPS
-3
Div Yield
-
P/E
-4
Market Cap
1,078,343,711
Overview
Related Instruments
ARKG
ARKG
D
ARK Genomic Revolution ETF
48.160
0.290(0.61%)
48.580+0.420(+0.87%)
BEAM
D
Beam Therapeutics
24.035
-0.515(-2.10%)
BNGO
D
Bionano Genomics
1.14000
-0.04000(-3.39%)
CLOU
CLOU
D
Global X Cloud Computing ETF
30.310
0.650(2.19%)
30.620+0.310(+1.02%)
CRSP
D
CRISPR Therapeutics AG
49.370
-0.600(-1.20%)
49.430+0.060(+0.12%)
EDIT
D
Editas Medicine
2.38500
-0.09500(-3.83%)
FATE
D
Fate Therapeutics
2.10500
0.00000(0.00%)
NTLA
D
Intellia Therapeutics
11.205
0.050(0.45%)
11.210+0.005(+0.04%)
TDOC
D
Teladoc Health
6.34500
0.02500(0.40%)
More

Title: Replimune Group

Sector: Healthcare
Industry: Biotechnology
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.